D.A. Davidson & CO. Boosts Stock Holdings in Guardant Health, Inc. (NASDAQ:GH)

D.A. Davidson & CO. raised its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 72.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 42,380 shares of the company’s stock after purchasing an additional 17,755 shares during the period. D.A. Davidson & CO.’s holdings in Guardant Health were worth $1,295,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Lord Abbett & CO. LLC bought a new stake in shares of Guardant Health in the 3rd quarter valued at about $15,624,000. Guyasuta Investment Advisors Inc. bought a new stake in shares of Guardant Health in the 4th quarter valued at about $206,000. Cerity Partners LLC boosted its holdings in shares of Guardant Health by 54.6% in the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock valued at $4,473,000 after buying an additional 68,883 shares in the last quarter. Geode Capital Management LLC boosted its stake in Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock worth $64,754,000 after purchasing an additional 29,686 shares in the last quarter. Finally, Entropy Technologies LP acquired a new stake in Guardant Health in the 4th quarter worth approximately $377,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Trading Down 9.6 %

Shares of GH stock opened at $42.87 on Friday. The company’s 50-day moving average price is $40.19 and its 200-day moving average price is $31.59. The stock has a market cap of $5.30 billion, a price-to-earnings ratio of -12.04 and a beta of 1.32. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $50.89.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. As a group, equities research analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Guggenheim reiterated a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. JPMorgan Chase & Co. raised their price target on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday. Barclays started coverage on shares of Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price for the company. Raymond James reaffirmed an “outperform” rating and set a $59.00 target price (up from $39.00) on shares of Guardant Health in a report on Friday. Finally, The Goldman Sachs Group boosted their price target on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday. Eighteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $44.78.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 2,768 shares of company stock valued at $98,798 over the last 90 days. 5.50% of the stock is owned by insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.